X4 Pharmaceuticals Inc (XFOR)
0.353
+0.08
(+28.69%)
USD |
NASDAQ |
Nov 14, 12:14
X4 Pharmaceuticals Enterprise Value: -47.50M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -47.50M |
| November 12, 2024 | 6.045M |
| November 11, 2024 | 18.02M |
| November 08, 2024 | 10.32M |
| November 07, 2024 | 10.19M |
| November 06, 2024 | 3.820M |
| November 05, 2024 | -0.0046M |
| November 04, 2024 | -4.133M |
| November 01, 2024 | -6.273M |
| October 31, 2024 | -9.441M |
| October 30, 2024 | -6.273M |
| October 29, 2024 | -9.896M |
| October 28, 2024 | -9.474M |
| October 25, 2024 | -11.83M |
| October 24, 2024 | -12.09M |
| October 23, 2024 | -8.733M |
| October 22, 2024 | -8.598M |
| October 21, 2024 | -10.15M |
| October 18, 2024 | -6.188M |
| October 17, 2024 | -10.03M |
| October 16, 2024 | -3.914M |
| October 15, 2024 | 0.0965M |
| October 14, 2024 | 0.2819M |
| October 11, 2024 | -7.503M |
| October 10, 2024 | -5.447M |
| Date | Value |
|---|---|
| October 09, 2024 | -4.251M |
| October 08, 2024 | -2.566M |
| October 07, 2024 | -4.638M |
| October 04, 2024 | 10.95M |
| October 03, 2024 | 12.38M |
| October 02, 2024 | 8.960M |
| October 01, 2024 | 13.31M |
| September 30, 2024 | 19.05M |
| September 27, 2024 | 16.64M |
| September 26, 2024 | 17.49M |
| September 25, 2024 | 14.65M |
| September 24, 2024 | 26.87M |
| September 23, 2024 | 25.25M |
| September 20, 2024 | 25.41M |
| September 19, 2024 | 25.51M |
| September 18, 2024 | 24.76M |
| September 17, 2024 | 24.70M |
| September 16, 2024 | 17.91M |
| September 13, 2024 | 25.91M |
| September 12, 2024 | 20.52M |
| September 11, 2024 | 22.17M |
| September 10, 2024 | 22.54M |
| September 09, 2024 | 18.31M |
| September 06, 2024 | 16.05M |
| September 05, 2024 | 20.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-47.50M
Minimum
Nov 13 2024
334.10M
Maximum
Jun 13 2023
71.65M
Average
61.95M
Median
Jun 25 2020
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 3.432M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
| Theriva Biologics Inc | -13.26M |
| Oragenics Inc | 2.142M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 90.83M |
| Revenue (Quarterly) | 0.563M |
| Total Expenses (Quarterly) | 34.46M |
| EPS Diluted (Quarterly) | 0.45 |
| Gross Profit Margin (Quarterly) | 52.40% |
| Earnings Yield | 25.50% |
| Normalized Earnings Yield | -171.44 |